Comprehensive Evaluation of Tirbanibulin for Treating Actinic Keratosis: A European Multi-Criteria Decision Analysis Study - Takeaways - MDSpire

Comprehensive Evaluation of Tirbanibulin for Treating Actinic Keratosis: A European Multi-Criteria Decision Analysis Study

  • By

  • Carola Berking

  • Rafael Botella

  • Andrea Carugno

  • Giovanna Gambarelli

  • Josep Malvehy

  • Elvira Moscarella

  • Arianna Petracca

  • Gregorio Romero

  • Julio Sosa

  • Eggert Stockfleth

  • Jose Luis Trillo

  • March 12, 2026

  • 0 min

Share

  • 1

    Actinic keratosis is a prevalent skin condition that can progress to cutaneous squamous cell carcinoma, necessitating effective long-term treatments.

  • 2

    The study compared tirbanibulin and 5-fluorouracil 4% for treating actinic keratosis using multi-criteria decision analysis involving stakeholders from three European countries.

  • 3

    Tirbanibulin scored positively in safety, tolerability, and evidence quality, with efficacy ratings similar to 5-fluorouracil 4%.

  • 4

    Stakeholders emphasized the importance of safety and evidence strength, which may influence treatment adoption and reimbursement decisions.

  • 5

    The study highlights the need for further research on long-term control of actinic keratosis and its progression to cutaneous squamous cell carcinoma.

Original Source(s)

Related Content